Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent advances in the understanding of the molecular basis of cancer have translated to the development of effective therapeutic modalities for certain types of malignant tumors. Significant percentages of solid tumors present with locally advanced or metastastic disease for which systemic chemotherapy, with or without radiotherapy, is the only treatment option. Cytotoxic drugs discovered by the screening of natural compounds or by medicinal chemistry are the mainstay of our current chemotherapy armamentarium for cancers. Only incremental improvements of therapeutic benefits have been achieved with the testing of different combinations and permutations of standard cytotoxic drugs given at maximal tolerable doses, leading to the notion that a therapeutic plateau has been reached for cancer chemotherapy. This provides impetus for the development of more innovative therapeutic strategies using newer drug schedules and novel agents targeting signal transduction pathways or cellular processes essential for cancer growth and metastasis. An overview of lung cancer therapy is used in this paper to illustrate the evolving paradigm of modern oncology. The future of cancer chemotherapy will most likely be a hybrid of cytotoxic drugs combined with molecularly targeted agents that are individually tailored to the patient's specific genotype and phenotype. In this context, chemical libraries derived from natural products have the potential to identify novel agents with complex structure, chirality, and multiple pharmacophores suitable to interfere with single or multiple cancer targets.

Original languageEnglish
Title of host publicationAlternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs
PublisherSpringer US
Pages3-21
Number of pages19
ISBN (Print)9781441900197
DOIs
StatePublished - Dec 1 2010

Fingerprint

Lung Neoplasms
Neoplasms
Drug Therapy
Therapeutics
Pharmaceutical Preparations
Small Molecule Libraries
Preclinical Drug Evaluations
Pharmaceutical Chemistry
Biological Products
Signal Transduction
Appointments and Schedules
Radiotherapy
Genotype
Neoplasm Metastasis
Phenotype
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nguyen, D. (2010). Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study. In Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs (pp. 3-21). Springer US. https://doi.org/10.1007/978-1-4419-0020-3_1

Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study. / Nguyen, Dao.

Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs. Springer US, 2010. p. 3-21.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nguyen, D 2010, Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study. in Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs. Springer US, pp. 3-21. https://doi.org/10.1007/978-1-4419-0020-3_1
Nguyen D. Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study. In Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs. Springer US. 2010. p. 3-21 https://doi.org/10.1007/978-1-4419-0020-3_1
Nguyen, Dao. / Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study. Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs. Springer US, 2010. pp. 3-21
@inbook{0ec26ade258f44c991a371d77bcf688d,
title = "Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study",
abstract = "Recent advances in the understanding of the molecular basis of cancer have translated to the development of effective therapeutic modalities for certain types of malignant tumors. Significant percentages of solid tumors present with locally advanced or metastastic disease for which systemic chemotherapy, with or without radiotherapy, is the only treatment option. Cytotoxic drugs discovered by the screening of natural compounds or by medicinal chemistry are the mainstay of our current chemotherapy armamentarium for cancers. Only incremental improvements of therapeutic benefits have been achieved with the testing of different combinations and permutations of standard cytotoxic drugs given at maximal tolerable doses, leading to the notion that a therapeutic plateau has been reached for cancer chemotherapy. This provides impetus for the development of more innovative therapeutic strategies using newer drug schedules and novel agents targeting signal transduction pathways or cellular processes essential for cancer growth and metastasis. An overview of lung cancer therapy is used in this paper to illustrate the evolving paradigm of modern oncology. The future of cancer chemotherapy will most likely be a hybrid of cytotoxic drugs combined with molecularly targeted agents that are individually tailored to the patient's specific genotype and phenotype. In this context, chemical libraries derived from natural products have the potential to identify novel agents with complex structure, chirality, and multiple pharmacophores suitable to interfere with single or multiple cancer targets.",
author = "Dao Nguyen",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/978-1-4419-0020-3_1",
language = "English",
isbn = "9781441900197",
pages = "3--21",
booktitle = "Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs",
publisher = "Springer US",

}

TY - CHAP

T1 - Overview of efficacy and limitation of standard and targeted therapy for malignant disease using lung cancer as a case study

AU - Nguyen, Dao

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Recent advances in the understanding of the molecular basis of cancer have translated to the development of effective therapeutic modalities for certain types of malignant tumors. Significant percentages of solid tumors present with locally advanced or metastastic disease for which systemic chemotherapy, with or without radiotherapy, is the only treatment option. Cytotoxic drugs discovered by the screening of natural compounds or by medicinal chemistry are the mainstay of our current chemotherapy armamentarium for cancers. Only incremental improvements of therapeutic benefits have been achieved with the testing of different combinations and permutations of standard cytotoxic drugs given at maximal tolerable doses, leading to the notion that a therapeutic plateau has been reached for cancer chemotherapy. This provides impetus for the development of more innovative therapeutic strategies using newer drug schedules and novel agents targeting signal transduction pathways or cellular processes essential for cancer growth and metastasis. An overview of lung cancer therapy is used in this paper to illustrate the evolving paradigm of modern oncology. The future of cancer chemotherapy will most likely be a hybrid of cytotoxic drugs combined with molecularly targeted agents that are individually tailored to the patient's specific genotype and phenotype. In this context, chemical libraries derived from natural products have the potential to identify novel agents with complex structure, chirality, and multiple pharmacophores suitable to interfere with single or multiple cancer targets.

AB - Recent advances in the understanding of the molecular basis of cancer have translated to the development of effective therapeutic modalities for certain types of malignant tumors. Significant percentages of solid tumors present with locally advanced or metastastic disease for which systemic chemotherapy, with or without radiotherapy, is the only treatment option. Cytotoxic drugs discovered by the screening of natural compounds or by medicinal chemistry are the mainstay of our current chemotherapy armamentarium for cancers. Only incremental improvements of therapeutic benefits have been achieved with the testing of different combinations and permutations of standard cytotoxic drugs given at maximal tolerable doses, leading to the notion that a therapeutic plateau has been reached for cancer chemotherapy. This provides impetus for the development of more innovative therapeutic strategies using newer drug schedules and novel agents targeting signal transduction pathways or cellular processes essential for cancer growth and metastasis. An overview of lung cancer therapy is used in this paper to illustrate the evolving paradigm of modern oncology. The future of cancer chemotherapy will most likely be a hybrid of cytotoxic drugs combined with molecularly targeted agents that are individually tailored to the patient's specific genotype and phenotype. In this context, chemical libraries derived from natural products have the potential to identify novel agents with complex structure, chirality, and multiple pharmacophores suitable to interfere with single or multiple cancer targets.

UR - http://www.scopus.com/inward/record.url?scp=84885753584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885753584&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0020-3_1

DO - 10.1007/978-1-4419-0020-3_1

M3 - Chapter

AN - SCOPUS:84885753584

SN - 9781441900197

SP - 3

EP - 21

BT - Alternative and Complementary Therapies for Cancer: Integrative Approaches and Discovery of Conventional Drugs

PB - Springer US

ER -